Drugs / Recombinant COVID-19 vaccine(CHO cell)
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05033847 | Sep 2021 → Nov 2023 | Orthocoronavirinae infectious disease, pneumonia | National Vaccine and Serum Institute, China | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05765604 Comparator | Mar → Jul 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT05770180 Comparator | Mar → Jul 2023 | COVID-19 | WestVac Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Recombinant COVID-19 vaccine (CHO cell) | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05770180 ↗ |
| Modality | Vaccine | “Recombinant COVID-19 Vaccine (CHO cell)” NCT05033847 ↗ |
| Route | Intramuscular | “Intramuscular injection of Recombinant COVID-19 Vaccine (CHO cell) in the deltoid muscle of the upper arm” NCT05033847 ↗ |